key: cord-0962408-9f7c9lg5
authors: Davies, Katherine; Buczkowski, Hubert; Welch, Stephen R; Green, Nicole; Mawer, Damian; Woodford, Neil; Roberts, Allen DG; Nixon, Peter J; Seymour, David W; Killip, Marian J
title: Effective in-vitro inactivation of SARS-CoV-2 by commercially available mouthwashes
date: 2020-12-02
journal: bioRxiv
DOI: 10.1101/2020.12.02.408047
sha: 145915ec79d35f9df23765c7b39b0567cffccdfb
doc_id: 962408
cord_uid: 9f7c9lg5

Infectious SARS-CoV-2 can be recovered from the oral cavities and saliva of COVID-19 patients with potential implications for disease transmission. Reducing viral load in patient saliva using antiviral mouthwashes may therefore have a role as a control measure in limiting virus spread, particularly in dental settings. Here, the efficacy of SARS-CoV-2 inactivation by seven commercially available mouthwashes with a range of active ingredients were evaluated in vitro. We demonstrate ≥4.1 to ≥5.5 log10 reduction in SARS-CoV-2 titre following a one minute treatment with commercially available mouthwashes containing 0.01-0.02% stabilised hypochlorous acid or 0.58% povidone iodine, and non-specialist mouthwashes with both alcohol-based and alcohol-free formulations designed for home use. In contrast, products containing 1.5% hydrogen peroxide or 0.2% chlorhexidine gluconate were ineffective against SARS-CoV-2 in these tests. This study contributes to the growing body of evidence surrounding virucidal efficacy of mouthwashes/oral rinses against SARS-CoV-2, and has important applications in reducing risk associated with aerosol generating procedures in dentistry and potentially for infection control more widely.

and alcohol-free formulations designed for home use. In contrast, products 48 containing 1.5% hydrogen peroxide or 0.2% chlorhexidine gluconate were 49 ineffective against SARS-CoV-2 in these tests. This study contributes to the 50 growing body of evidence surrounding virucidal efficacy of mouthwashes/oral 51 rinses against SARS-CoV-2, and has important applications in reducing risk 52 associated with aerosol generating procedures in dentistry and potentially for 53 infection control more widely. SARS-CoV-2 is the virus responsible for causing , and infectious 72 SARS-CoV-2 is detectable in the oral cavities and the saliva of COVID-19 73 patients (2, 3) with potential implications for disease transmission. Aerosol-74 generating procedures, particularly in the dental setting, therefore pose a 75 potential infectious risk to health care teams working in close proximity to 76 patients while these procedures are being carried out (4). The World Health 77

Organization recommends the use of pre-procedural mouth rinses for the 78 reduction of SARS-CoV-2 viral load in patient saliva as a control measure for 79 reduction of this infectious risk (5). Here, we have assessed seven different 80 commercially available mouthwashes with a range of active ingredients for the 81 efficacy against SARS-CoV-2 in vitro. 82

The commercial mouthwashes tested in this study are listed in Table 1 . All 84 products were stored in their original packaging according to manufacturer's 85 instructions and were unopened prior to testing. In vitro SARS-CoV-2 86 inactivation assessments were performed in a containment level 3 facility, and 87 all virus manipulations were performed within a class III microbiological safety 88 cabinet. Briefly, one volume of virus preparation (SARS-CoV-2 England 2 89 strain, in tissue culture fluid [TCF] comprising Minimum Essential Media 90

[MEM] and 5% foetal calf serum) was mixed with ten volumes of product and 91 mixed well by inversion. Products were incubated at 20°C (+/-2°C) for one 92 minute, then immediately titrated in phosphate-buffered saline (PBS) to 93 generate a ten-fold dilution series. Dilution series were directly applied to 96-94 well plates of Vero E6 cells to determine the 50% tissue culture infectious 95 dose (TCID50) as previously described (6). All products were tested in 96 triplicate, and a triplicate set of samples treated with an equivalent volume of 97 PBS was included in each experiment as a control for virus recovery. Mean 98 titre reductions were calculated by subtracting the mean log 10 titre of treated 99 samples from the mean log 10 titre of PBS-treated samples. The cytotoxicity of 100 treated samples varied between products, and a cytotoxic control sample comprising one volume of PBS to ten volumes of product was evaluated in 102 parallel and used to calculate the limit of detection for each product. 103 104 Two Listerine compositions were evaluated in this study: Listerine Advanced 105

Defence Sensitive and alcohol-free Listerine Total Care. Both formulations 106 reduced SARS-CoV-2 titre to below the limit of detection for the tests after a 107 one minute treatment: ≥ 3.5 log 10 reduction for Listerine Advanced Defence 108

Sensitive and ≥ 4.1 log 10 reduction for Listerine Total Care, respectively (Table  109 1). The high level of cytotoxicity associated with Listerine Advanced Defence 110

Sensitive meant that the reduction we could demonstrate for this product in 111 this test was below the >4 log 10 reduction given in the standard for virucidal 112 quantitative suspension tests, BS EN 14476 (7). Previously, we have 113 conducted a wide range of chemical inactivation testing to inform risk 114 assessments around sample processing for the COVID-19 response (6, 8); 115 we have used purification methods extensively for these assessments to 116 remove components that are cytotoxic in cell culture and would otherwise 117 increase the limit of detection for treated samples. However, we have found 118 these methods unsuitable for evaluation of short (e.g. two minutes or less) 119 treatment times due to the additional time required for sample processing. To 120 see if we could increase the detectable titre reduction without performing a 121 post-treatment purification step, we tested these products using a 122 concentrated virus preparation, generated by concentrating TCF containing 123 virus through 100-kDa-cutoff Amicon Ultra-15 centrifugal filters. When tested 124 against this concentrated virus, we could demonstrate Povident contains 0.58% povidone iodine, and reduced SARS-CoV-2 titre by 140 ≥ 4.1 log 10 in our tests using unconcentrated TCF and ≥ 5.2 log 10 using 141 concentrated TCF (Table 1) . This is consistent with previous studies of 142 povidone iodine-based products, where efficacy in vitro against coronaviruses 143 has been demonstrated, including against SARS-CoV-1 and Middle East 144 respiratory syndrome-associated coronavirus MERS-CoV (12, 13). More 145 recently, oral rinse products containing between 0.5% and 1.0% povidone 146

iodine have been demonstrated to be effective against SARS-CoV-2 in vitro 147 (9, 10, 14, 15) and in reducing viral load in the saliva of human COVID-19 148 patients (16). 149 150 OraWize+, a product containing 0.01-0.02% hypochlorous acid (HOCl) as its 151 active ingredient, reduced virus titre in unconcentrated TCF by ≥ 5.5 log 10 152 TCID50/ml, to below the limit of detection for the assay (Table 1) . A potential 153 role for hypochlorous acid-based products as oral rinses to combat SARS-154

CoV-2 has been proposed (17, 18), but to our knowledge this is the first in 155 vitro evidence for efficacy of a hypochlorous acid-based mouthwash against 156 SARS-CoV-2. It is important to note however that OraWize+ was not effective 157 when tested against concentrated TCF (Table 1) , potentially due to high levels 158 of protein in this sample matrix, suggesting that the chemistry of this product 159 may be affected by complex samples types. This is an observation we have 160 also made for other hypochlorous acid-based inactivants (unpublished data) 161 and further testing is required to determine the significance of this observation 162 for product use. 163 164 Two chlorhexidine gluconate-based products were evaluated in this study: 165

Corsodyl (alcohol-free) and Ecolabs Chlorhexidine Gluconate Antiseptic Wash 166 (containing ethanol). Neither were effective at inactivating SARS-CoV-2 167 (Table 1) , consistent with previous studies demonstrating only a very small 168 effect on SARS-CoV-2 (9, 10). Peroxyl (containing 1.5% hydrogen peroxide) was similarly ineffective. This last observation was initially surprising 170 considering that one minute treatment with 0.5% hydrogen peroxide has been 171 reported to be effective against human coronavirus 229E in virus suspension 172 tests (19) and that 1% hydrogen peroxide pre-procedural mouth rinse is 173 recommended by the World Health Organisation (WHO) and others for 174 reduction of infectious risks in the context of COVID-19 (4, 5). However, ours 175

is not the only study to demonstrate minimal in vitro effectiveness of hydrogen 176 peroxide-based mouth rinses against SARS-CoV-2 and the superior 177 effectiveness of other types of oral rinses (9, 15) . 178

The availability and stability of these products vary, and these factors may 180 impact their utility in different settings. OraWize+ has a much shorter shelf life 181 than other products tested (one month after opening) and must be protected 182 from light; we have found that it can lose effectiveness when stored incorrectly 183 ≥ 5.2* (4. 9-5.4) 

Virucidal Efficacy of Different Oral Rinses Against Severe Acute 250

Respiratory Syndrome Coronavirus 2

Brief 253 Report: The Virucidal Efficacy of Oral Rinse Components Against SARS-CoV-254

257 Lowering the transmission and spread of human coronavirus

Medical Virology. 2020. In press

Bactericidal and Virucidal Efficacy of Povidone-Iodine Gargle/Mouthwash 262 Against Respiratory and Oral Tract Pathogens. Infectious Diseases and 263 Therapy

Inactivation of SARS Coronavirus by 266 Means of Povidone-Iodine, Physical Conditions and Chemical Reagents. 267 Dermatology

Povidone-Iodine Demonstrates Rapid

Vitro Virucidal Activity Against SARS-CoV-2, The Virus Causing COVID-19

275 Comparison of In Vitro Inactivation of SARS CoV-2 with Hydrogen Peroxide 276 and Povidone-Iodine Oral Antiseptic Rinses

Is povidone iodine 281 mouthwash effective against SARS-CoV-2? First in vivo tests

Banakar 288 MH, MohammadSadeghi A. COVID-19 transmission risk and protective 289 protocols in dentistry: a systematic review

Persistence of 292 coronaviruses on inanimate surfaces and their inactivation with biocidal 293 agents

The views expressed in this article are those of the authors and are not 206 necessarily those of Public Health England, the National Health Service or the 207